Recent Updates
Recently added Catalysts
ADRX Positive Sentiment

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting

Key Takeaway: ADARx Pharmaceuticals announced it will present Phase 1/2 data and Phase 3 design for onvuzosiran (ADX-324) at the 2026 AAAAI Annual Meeting. This investigational siRNA therapy targets hereditary angioedema (HAE) by inhibiting prekallikrein. The presentation is scheduled for February 27, 2026, in Philadelphia, PA.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of promising Phase 1/2 data
  • Innovative siRNA therapy for hereditary angioedema
  • Potential for greater control of kallikrein activity
  • Orphan Drug Designation received from the FDA

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~106 mo
Minimal dilution risk
Lead asset
ADX-324
Phase 3 · Hereditary Angioedema

Full Press Release Details

SAN DIEGO, Calif. ­­– February 20, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present Phase 1/2 clinical data and Phase 3 design for its onvuzosiran (also known asADX-324) program, an investigational small interfering RNA (siRNA) therapeutic candidate being evaluated in a Phase 3 clinical trial for the treatment of hereditary angioedema (HAE). The poster presentation will be given at the 2026 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) being held February 27 – March 2, 2026, in Philadelphia, PA.
Presentation details:
• “ADX-324, A Semi-Annual SC Investigational siRNA Targeting Prekallikrein for HAE Attack Prevention” (Poster number: 089) on Friday, February 27, 2026 from 2:45 – 3:45 pm EST in the Pennsylvania Convention Center, Level 2, Hall E
About HAE and Onvuzosiran (ADX-324)
HAE is a rare genetic disorder characterized by recurrent, unpredictable attacks of swelling that can be painful, disabling, and life-threatening. These attacks result from dysregulation of the kallikrein-kinin system (KKS), which regulates blood pressure, inflammation, coagulation and pain. Prekallikrein (PKK) is a critical protein in the plasma kallikrein pathway that activates a second protein called kallikrein, which, if present, produces bradykinin, a potent vasodilator. A dysfunctional KKS leads to excessive release of bradykinin which causes the swelling attacks in HAE.
Onvuzosiranis an investigational siRNA therapy designed to inhibit PKK generation at the mRNA level and reduce the production of plasma PKK, thereby averting bradykinin generation and potentially preventing HAE attacks. Compared to currently approved prophylactic treatments, Onvuzosiranis expected to decrease PKK to a greater degree, offering the potential for greater and more durable control of kallikrein activity, which is expected to result in a higher proportion of patients remaining attack-free with a less frequent dosing regimen. Onvuzosiranis currently being evaluated in the Phase 3 STOP-HAE clinical trial ( https://stophae.com ) and has received Orphan Drug Designation for the treatment of patients with HAE from the U.S. Food and Drug Administration (FDA).
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. We have developed technology to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with urgent unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. Follow ADARx on LinkedIn .

Frequently Asked Questions

What is onvuzosiran (ADX-324)?

Onvuzosiran is an investigational siRNA therapy targeting prekallikrein for HAE.

When will ADARx present its clinical data?

ADARx will present its data on February 27, 2026, at the AAAAI Annual Meeting.

What condition is onvuzosiran being developed for?

Onvuzosiran is being developed for the treatment of hereditary angioedema (HAE).

What is the significance of Orphan Drug Designation?

Orphan Drug Designation helps expedite the development of treatments for rare diseases.

Last updated: Feb 20, 2026